Merus NV
- Country
- 🇳🇱Netherlands
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 229
- Market Cap
- $3.6B
- Website
- http://www.merus.nl
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab Vs Pembrolizumab in First-line Treatment of Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: PetosemtamabDrug: Pembrolizumab
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 500
- Registration Number
- NCT06525220
- Locations
- 🇰🇷
Site 45, Seoul, Korea, Republic of
🇺🇸Site 36, La Jolla, California, United States
🇺🇸Site 43, Philadelphia, Pennsylvania, United States
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: PetosemtamabDrug: Investigator's Choice
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 500
- Registration Number
- NCT06496178
- Locations
- 🇺🇸
Site 46, San Francisco, California, United States
🇺🇸Site 49, Maple Grove, Minnesota, United States
🇺🇸Site 50, Charleston, South Carolina, United States
Study Evaluating Zenocutuzumab in Patients with or Without Molecularly Defined Cancers
- Conditions
- NSCLC Harboring NRG1 FusionMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 90
- Registration Number
- NCT05588609
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation, Whittier, California, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Conditions
- Non-Small Cell Lung Cancer MetastaticColorectal CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 576
- Registration Number
- NCT04868877
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori Regina Elena, Roma, Rome, Italy
🇮🇹Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy
🇺🇸START Mountain Region, West Valley City, Utah, United States
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- Conditions
- NRG1 FusionPancreatic CancerNon Small Cell Lung CancerSolid Tumor, Unspecified, AdultProstate CancerHead and Neck CancerColorectal CancerBreast CancerCholangiocarcinomaRenal Cell Carcinoma
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Merus N.V.
- Registration Number
- NCT04100694
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
- Conditions
- B-cell Lymphoma, AdultSolid Tumor, AdultAdvanced Cancer
- Interventions
- Drug: MCLA-145Drug: Pembrolizumab (Keytruda)
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 72
- Registration Number
- NCT03922204
- Locations
- 🇺🇸
Moores Cancer Centre, La Jolla, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Conditions
- Head and Neck Squamous Cell CarcinomaGastric CancerNSCLCAdvanced/Metastatic Solid TumorsHNSCCColorectal CancerGastroesophageal-junction Cancer
- Interventions
- Combination Product: MCLA-158 + FOLFIRIDrug: MCLA-158Combination Product: MCLA-158 + Pembrolizumab
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 567
- Registration Number
- NCT03526835
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 105
- Registration Number
- NCT03321981
- Locations
- 🇵🇹
Champalimaud Clinical Centre, Lisbon, Portugal
🇵🇹Hopistal San Antonio, Porto, Portugal
🇪🇸Instituto Valenciano de Oncologia, Valencia, Spain
MCLA-117 in Acute Myelogenous Leukemia
- Conditions
- Acute Myelogenous LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: MCLA-117 bispecific antibody
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 62
- Registration Number
- NCT03038230
- Locations
- 🇮🇹
Fondazione Policlinico Tor Vergata, Rome, Italy
🇫🇷Institut Gustave Roussy, Villejuif Cedex, Ile-de-France, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
- Conditions
- NSCLC Harboring NRG1 FusionPancreatic Cancer Harboring NRG1 FusionNRG1 FusionSolid Tumours Harboring NRG1 Fusion
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 250
- Registration Number
- NCT02912949
- Locations
- 🇯🇵
National Cancer Center East, Tokyo, Japan
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University College of Medicine, Seoul, Korea, Republic of